Movement Alert|INNOVENT BIO Falls 3.06% in Regular Trading, prior Phase III hyperlipidemia trial catalyst fades after recent rally

Market Focus11-11

On November 11, INNOVENT BIO fell 3.06% in Regular Trading, trading at HK$85.55, with turnover of HK$205 million.

The most relevant recent catalyst in public information was the company’s November 9 announcement that its Phase III CREDIT-5 study met the primary endpoint for Sintbilo as a first-line monotherapy in non-familial hypercholesterolemia and mixed hyperlipidemia, but the latest market alert indicates the stock turned lower after that positive update.

Background data show the 198-patient China study delivered significant LDL-C reduction versus placebo at week 12, with favorable safety and no severe or serious treatment-emergent adverse events or new safety signals disclosed. The product is described as the first domestic PCSK9 antibody launched in China and had already been added to the national reimbursement drug list effective January 1, supporting its commercial positioning. Earlier, the company also disclosed third-quarter product revenue of more than RMB4.7 billion, up more than 40% year over year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment